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Disturbances in Panic Disorder
Geneviève Belleville and Alenka Potočnik
Abstract
The nature and prevalence of sleep disturbances in panic disorder (PD) have 
been often discussed but remain unclear. The objective of this systematic review and 
meta-analysis is to document sleep disturbances in PD. Systematic database search and 
standardized extraction were conducted. Meta-analysis was computed on self-report 
(subjective) and polysomnographic (PSG) (objective) data and on prevalence rates of 
nocturnal panic attacks (NPA). Of the 1262 publications retrieved, 31 were included. 
PD patients were compared to healthy controls on subjective and objective measures. 
Patients had higher Pittsburgh sleep quality index (PSQI) global scores (hedges’ 
g = 1.306, 95% CI [0.532, 2.081]), longer PSG sleep latency (hedges’ g = 0.81, 95% 
CI [0.576, 1.035]), poorer PSG sleep efficiency (hedges’ g = −0.79, 95% CI [−1.124, 
−0.432]), and shorter stage 2 (hedges’ g = 0.70, 95% CI [−1.231, −0.120]) and total 
sleep time (hedges’ g = −0.739, 95% CI [−1.127, −0.351]). Among patients, 52.1% (95% 
CI [0.464, 0.577]) reported NPA (≥1/lifetime). Patients with PD demonstrate subjec-
tive and objective sleep alterations. More than half have experienced NPA. These sleep 
disturbances could have a significant role in maintaining PD symptoms.
Keywords: panic disorder, nocturnal panic attacks, insomnia, sleep, sleep 
disturbances, meta-analysis
1. Introduction
Panic disorder (PD) is a common anxiety disorder, with a prevalence rate of 
3.7% in the general population [1]. It is characterized by sudden and recurrent 
surges of anxiety known as panic attacks, apprehensiveness about panic, and avoid-
ance of potential future panic attacks [2]. In PD, as in many anxiety disorders [3], 
sleep may be affected. The existing literature describes two primary types of sleep 
problems in patients with PD: insomnia and nocturnal panic attacks (NPA).
1.1 Insomnia in patients with PD
DSM-IV-TR defines insomnia as difficulty initiating or maintaining sleep, early 
awakening, or non-restorative sleep [4]. Symptoms must be present at least three 
times per week for at least 1 month and must be the source of significant distress or 
dysfunction [4]. Compared to DSM-IV-TR, DSM-5 added new criteria for insomnia, 
including early awakening and dissatisfaction with sleep quality [2]. Furthermore, 
the minimum duration of symptoms was increased to 3 months [2]. Insomnia 
is assessed using a wide variety of measures that can be generally classified as 
subjective or objective. The former uses self-report questionnaires and diaries or 
Psychopathology - An International and Interdisciplinary Perspective
2
clinician-rated assessments; the latter uses physiological measures such as polysom-
nography or actigraphy [5].
1.2 Nocturnal panic attacks
NPA are paroxysmal events characterized by abrupt awakening in a state of 
intense anxiety and discomfort [6]. In contrast with panic attacks that begin after 
waking, individuals experiencing NPA wake up in a state of panic [2]. Nocturnal 
panic attacks generally occur between stage 2 and stage 3 sleep and are not associated 
with the content of a nightmare [6]. In the majority of cases, daytime panic attacks 
are more frequent than NPA. However, a minority of patients primarily experience 
nocturnal panic attacks [7], and cases of individuals with exclusively nocturnal panic 
attacks have been reported [8]. Nocturnal panic attacks can be assessed using the NPA 
appendix from the anxiety disorders interview schedule for DSM-IV. This clinician-
administered interview thoroughly assesses NPA and includes questions relating to 
NPA frequency, apprehensiveness about future NPA, and avoidance behaviors.
1.3 Why study sleep in panic disorder?
Disturbed sleep in patients with PD is associated with greater PD severity [9]. 
In a recent study, researchers found that there was a significantly higher prevalence 
of insomnia (insomnia severity index > 8) in patients with severe or moderate PD 
symptoms than in patients with mild symptoms [9]. In addition to being associated 
with symptom severity, sleep disturbances, specifically NPA, are associated with 
suicidal behavior [10].
Not only are sleep disturbances (insomnia and NPA) associated with greater PD 
severity and with suicidal behavior, they are also hypothesized to perpetuate panic 
symptoms. Researchers have proposed that insomnia, NPA, and panic interact and 
reinforce one another in a vicious cycle [11]. Studies of individuals from the general 
population revealed that one night of sleep deprivation increases general anxiety and 
physiological activation [12]. In a similar experiment with patients with PD, research-
ers observed panic attacks in 40% of patients after one night of sleep deprivation, 
although none of the participants had experienced a panic attack in the prior week 
[13]. In the same study, none of the control participants (healthy controls or patients 
with obsessive-compulsive disorder) reported a panic attack the following day [13]. 
Although the experience of insomnia is distinct from the experience of sleep depriva-
tion, patients with chronic insomnia can develop a sleep deficit [14]. Some researchers 
have therefore hypothesized that the effect of chronic insomnia could be comparable 
(although less intense) to the effect of sleep deprivation, resulting in increased gen-
eral activation and triggering panic attacks [11]. When an individual also experiences 
NPA, they may develop apprehensiveness about going to sleep [15]. Apprehensiveness 
can result in a delayed bedtime, thereby compounding lack of sleep, increasing 
general activation, and potentially triggering panic [11]. Furthermore, some patients 
with PD tend to experience distress and even panic attacks in states of relaxation or 
states of decreased vigilance [16, 17]. It is hypothesized that such a reaction may occur 
immediately prior to sleep in some patients and may disturb sleep onset.
1.4 Unresolved issues related to insomnia in patients with PD
1.4.1 Subjective sleep data
Numerous studies have reported subjective sleep data from patients with PD, 
collected using a wide variety of psychometric tools. For example, many studies 
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have used the Pittsburgh sleep quality index and report a general sleep quality index 
[18–21]. The Hamilton depression scale (HAM-D) is another frequently used scale 
that assesses difficulty initiating and maintaining sleep, as well as early awaken-
ings [22–25]. Moreover, some studies measure variables that are not included in the 
definition of insomnia, such as sleep duration [23]. This diversity of variables and 
measures complexifies comparison between studies and precludes a clear portrait of 
sleep alterations in PD.
1.4.2 Objective sleep data
In contrast to subjective sleep data, objective data is collected in a standardized 
fashion, generating results that are comparable across studies. However, despite 
greater uniformity in assessment, the literature on objective sleep data has yielded 
contradictory results. For example, some authors have reported poorer sleep 
efficiency in patients with PD in comparison to healthy controls [19, 26], whereas 
others report no difference between groups [27]. Similarly, inconsistent results 
have been published about slow-wave sleep (stages 3 and 4) and REM sleep latency 
[6, 22, 26–31]. The wealth of conflicting data is confusing and can lead to errone-
ous conclusions. For example, if two studies report a difference between PD and 
control groups in a given variable and two others report no difference, readers tend 
to conclude that no substantial difference exists, which may not be the case [32]. 
Among possible explanations, inconsistencies may be partly attributable to a lack of 
statistical power: indeed, polysomnographic studies tend to have small sample sizes 
due to their costly and complex nature.
1.5 Unresolved issues concerning the prevalence of NPA in patients with PD
The results of NPA prevalence studies vary significantly. For example, Schredl 
et al. [33] reported an NPA prevalence rate of 37%, whereas Stein et al. [20] 
reported a figure almost twice as high (68%). Moreover, different authors use 
different frequency criteria, ranging from “at least one lifetime NPA” [34–36], to 
“two to four NPA per year” [33], to “a minimum of four NPA per month” [37], or 
to “many times per week” [33]. A summary of the data is indicated in order to gain 
clarity on the rate of NPA in patients with PD.
1.6 The need for a systematic literature review and meta-analysis
The unanswered questions described above indicate a clear need for a more 
precise portrait of sleep disturbances in PD. A systematic review of the existing 
literature is warranted. Some authors have undertaken the effort in recent decades 
[38–41], but contradictory results from objective data and variations in the report-
ing of subjective data resulted in questions remaining about sleep alterations in the 
population. Lack of uniformity in NPA prevalence measurement and reporting 
yielded significant variability in prevalence rate estimates. Meta-analytic methodol-
ogy involves pooling all samples into one group to conduct a quantitative analysis 
of data from previous research, with greater statistical power than when analyzing 
each study’s data alone. This method would likely allow for a clearer interpretation 
of the current literature on the subject.
The present study was designed to systematically review the existing literature 
on sleep disturbances in PD. More precisely, the objectives were (1) to compare 
sleep in patients with PD to sleep in healthy controls and (2) to assess the prevalence 
rate of NPA in patients with PD. We hypothesized that the sleep of patients with PD 
would be significantly different from that of healthy controls.
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2. Method
The preferred reporting items for systematic reviews and meta-analysis 
(PRISMA) checklist was used to design the study and to report results based on best 
practices in the field of literature reviews and meta-analyses [42].
2.1 Literature research
We conducted a literature review in these databases: PsycNet, MedLine, 
ProQuest, Web of Knowledge, Cochrane, and Psychology and Behavioral Sciences 
Collection. Search terms used in PsycNet were “panic disorder” OR “panic attack” 
OR panic AND sleep OR “sleep disorders” OR insomnia OR “nocturnal panic” 
OR “sleep deprivation.” Search terms used in MedLine, Web of Knowledge, and 
Cochrane were panic OR “panic disorder” AND sleep OR “sleep initiation and 
maintenance disorders” OR dyssomnia OR “sleep deprivation.” Publication date was 
1980 (DSM-III year of publication) to May 2016 inclusive.
To retrieve gray literature (i.e., unpublished work or studies that are published 
outside widely available journals) [43], reference lists of selected articles were 
searched for potentially eligible articles regarding sleep in PD. The Laval University 
library was searched for book chapters addressing sleep in PD. Reference lists were 
screened for articles of interest. Inclusion of ProQuest and Web of Knowledge 
databases helped retrieve gray literature, as these sources contain theses, symposia, 
and convention papers, in addition to journal articles.
2.2 Article selection
The following inclusion criteria were used: (a) studies had to be published in 
English, French, or Spanish; (b) minimum participant age was 18 years; (c) to 
ensure population representativeness, studies including participants with comor-
bidities were accepted if PD was the primary diagnosis for at least one subgroup; 
(d) studies had to report quantitative group data for at least one sleep variable; 
(e) data on sleep disturbances had to include means, standard deviations, and 
group sizes for PD and control groups; (f) prevalence of NPA had to be reported 
in percentage or number of participants, and total sample size had to be included; 
(g) data had to be issued from self-report questionnaires, clinician-administered 
interviews, sleep diaries, polysomnography, or actigraphy; and (h) for subjec-
tive and objective sleep data, patients with PD had to be compared to a group of 
healthy controls (for the prevalence of nocturnal panic, no comparison group was 
necessary).
Studies that met the following criterion were excluded: (a) studies in which 
all patients with PD reported a physical disease or one of the following comorbid 
psychiatric disorders, schizophrenia, bipolar disorder, and alcohol or drug abuse or 
dependence, and (b) studies in which no data could be grouped using the following 
procedure:
Studies were classified and grouped on the basis of the measure they reported. 
For example, all studies reporting results on the Pittsburgh sleep quality index 
(PSQI) were grouped together, the same was done for the Hamilton rating scale 
(HAM-D), polysomnography, etc. For articles reporting NPA, grouping was 
carried out on the basis of the frequency criteria used. For example, all studies 
reporting the prevalence of patients who had at least one NPA in their lifetime 
were grouped together, all articles reporting the prevalence of patients having at 
least one NPA/month were grouped together, etc. Some articles reported data from 
specific sleep measures or NPA frequency criteria that were not repeated elsewhere. 
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Studies reporting data that could not be grouped with other data from at least one 
additional study were excluded.
2.3 Data extraction
Once reference retrieval was complete, each of the selected papers was reviewed, 
and data was extracted using a standardized rating form and coding manual. 
Extracted variables included information about the sample and sampling method, 
general methodology, and sleep characteristics (self-report sleep data, polysomno-
graphic/actigraphic data, and prevalence of NPA).
2.4 Inter-rater agreement
2.4.1 Article selection
To reduce selection bias, a second trained judge independently rated the eligibil-
ity of 30% of the retrieved literature. The results of the two judges’ ratings were 
compared, and cases of disagreement were discussed to reach consensus.
2.4.2 Data extraction
Five raters participated in data extraction. Four of the judges were undergradu-
ate psychology students, and one was a graduate psychology student (AP). A pilot 
coding was conducted, wherein all judges used the coding manual to rate the same 
Item Percentage inter-rater agreement
Study description
PD group sample size 100.0
Control group sample size 100.0
Mean age 88.2
Gender 73.1
Medication permitted or not 96.2
Percentage of participants taking medication 84.6
Psychometric instrument used to diagnose PD 82.7
Psychometric instrument used to assess sleep 100.0
Self-report data
Sleep variable—PD group 88.9
Sleep variable—control group 88.9
Polysomnographic data
Sleep variable—PD group 100.0
Sleep variable—control group 98.8
NPA
Percentage of sample reporting NPA 46.7
NPA frequency criterion 66.7
Note: NPA = nocturnal panic attack; PD = panic disorder.
Table 1. 
Inter-rater agreement.
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Figure 1. 
Study selection flow chart.
four studies. When training was complete, studies were randomly assigned to one 
of the four undergraduate judges. The graduate student acted as second judge and 
independently coded all studies. Regular meetings were held to review discrepan-
cies and reach consensus. In total, 29 of the 31 studies (93.5%) included in the 
meta-analysis were independently rated by two judges. The percentages of inter-
rater agreement were between 70 and 100% for the majority of coded variables 
(see details in Table 1). Lower agreement rates were observed on variables related 
to NPA, a finding that can be explained by a lack of precision in reports of NPA 
prevalence.
2.5 Data analysis
Results were analyzed using the comprehensive meta-analysis software, version 
3. Since the studies included in this review varied widely, a random effects model 
was used. Many of the studies had small sample sizes, in particular polysomno-
graphic studies. Hedges’ g was consequently chosen for effect size because of its 
correction for small samples [32]. Q and I2 were used to assess heterogeneity. For 
each analysis of significant results including three studies or more, Orwin’s fail-safe 
N was used to investigate publication bias. In these cases, a funnel plot was visually 
examined.
3. Results
A total of 1229 articles were screened for eligibility (Figure 1). Of the 1229,80 
initially met inclusion criteria. Forty-nine were subsequently excluded. A total 
of 31 studies were selected for review. The majority of studies with self-report or 
polysomnographic data reported no significant differences in age or gender ratio 
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between PD and control groups. Of the 31 studies analyzed, seven included par-
ticipants taking medication. Participants were medication-free in all but one of the 
polysomnographic studies. In all studies, PD diagnoses were made using validated 
diagnostic interviews. The majority of patient samples were recruited in clinics/
hospitals or were referred by a health professional. Control participants were mostly 
recruited through local media.
3.1 Self-report sleep data
Of the 31 selected articles, seven reported self-report data. All seven studies 
used the PSQI. The component scales of subjective sleep quality, sleep latency, 
sleep duration, sleep efficiency, sleep disturbances, daytime dysfunction, and the 
PSQI global score were analyzed. The sixth PSQI scale (medication use) was not 
analyzed because the variable was outside the scope of the present study. Pooled 
PD group size ranged from 47 to 182 participants (average = 94 participants). 
Pooled control groups ranged from 15,151 to 15,238 participants (average = 15,163 
participants) (Table 2). The wide difference between average group size in PD and 
control groups was due to the presence of one study whose control group was 15,117 
participants. When this study was removed from calculations of the average sample 
size, average control group size was 46 participants.
Analyses revealed that patients with PD had significantly greater scores than 
healthy controls for the PSQI scales of sleep quality, sleep latency, sleep distur-
bances, daily dysfunction, and global score. This means that patients with PD 
reported worse sleep quality, longer sleep latency, more sleep disturbances, and 
more daily dysfunction. All effect sizes were large as per Cohen’s criteria [44]. There 
were no significant differences between groups on PSQI sleep efficiency and sleep 
duration scales.
Variable Effect size 
(Hedges’ g)
95% CI Standard 
error
Variance Q I2 Number 
of 
studies
PD 
group 
sample 
size
Control 
group 
sample 
size
PSQI subjective 
sleep quality
1.76* [1.26, 
2.31]
0.28 0.08 — — 2 89 15,151
PSQI sleep 
latency
1.31* [0.42, 
2.21]
0.46 0.21 — — 2 89 15,151
PSQI sleep 
duration
−0.18 [−1.33, 
0.98]
0.59 0.35 — — 2 89 15,151
PSQI sleep 
efficiency
0.81 [−0.08, 
1.70]
0.45 0.21 — — 2 89 15,151
PSQI sleep 
disturbances
1.56* [0.65, 
2.47]
0.46 0.22 — — 2 89 15,151
PSQI daily 
dysfunction
1.71* [1.38, 
2.04]
0.17 0.03 — — 2 89 15,151
PSQI global 
score
1.31* [0.53, 
2.08]
0.40 0.16 69.38** 92.79 6 182 15,238
Note: PSQI = Pittsburgh sleep quality index; — = insufficient number of studies to report heterogeneity; 
CI = confidence interval.
*= Significant differences between groups, p < 0.05.
**= Significant heterogeneity, p < 0.05.
Table 2. 
Meta-analysis results for self-report data.
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To evaluate the consistency of data across studies, heterogeneity tests were 
performed on data for PSQI global score. The results indicated the presence of 
significant heterogeneity. Estimated variance in true effects (I2) was 92.8%. The 
small number of effect sizes precluded subgroup or meta-regression analyses that 
may have explained the heterogeneity of results.
Among subjective sleep variables, the impact of publication bias was assessed 
for PSQI global score. Results of Orwin’s fail-safe N indicated that 48 unpublished 
studies with no effect would be required to lower the combined effect for PSQI 
global score to 0.2 (criterion for trivial effect). Moreover, the analysis of the funnel 
plot revealed an uneven distribution of studies, the majority of which were below 
the mean Hedges’ g value. That is, both Orwin’s fail-safe N and funnel plot analysis 
suggest the possibility of publication bias due to a “file drawer effect” (i.e., fewer 
studies with unsignificant results are published). The results must therefore be 
interpreted with caution.
3.2 Polysomnographic sleep data
Of the 31 included studies, 15 reported polysomnographic or actigraphic data. 
Meta-analysis was performed with 18 variables: sleep latency, sleep efficiency, 
number of awakenings, total sleep time, total wake time, REM sleep characteristics 
(duration, density, percentage, latency, number of REM periods), slow-wave sleep 
characteristics (duration, percentage), duration of stage 1 and stage 2 sleep, and 
percentage of stages 1–4 sleep. Pooled samples sizes varied between 19 and 209 
participants for PD groups (average = 115 participants) and between 19 and 164 
participants for control groups (average = 86 participants) (Table 3).
Significant differences between PD and control groups were demonstrated for 
four variables. PD participants had longer sleep latency, lower sleep efficiency, 
and shorter total sleep time than healthy controls. Duration of stage 2 sleep was 
also shorter. Analyses for the 14 other sleep variables did not show statistical 
significance.
To evaluate the consistency of data across studies, heterogeneity tests were 
performed on data for sleep latency, sleep efficiency, and total sleep time. The 
results indicated the presence of significant heterogeneity for sleep efficiency and 
for total sleep time. For the former, estimated variance in true effects (I2) was 52%. 
For the latter, estimated variance in true effects (I2) was 68%. There was no sig-
nificant heterogeneity among sleep latency effect sizes. The small number of effect 
sizes precluded subgroup or meta-regression analyses that may have explained the 
heterogeneity of results.
We assessed the possibility of publication bias for the following variables: sleep 
latency, sleep efficiency, and total sleep time. For sleep latency, Orwin’s fail-safe N 
was 31 (criterion for trivial Hedges’ g = 0.2). This statistic indicates that it would 
take 31 studies with no effect to decrease the effect size to 0.2 or lower. Similar 
analysis yielded Orwin’s fail-safe N of 26 for sleep efficiency and 24 for total sleep 
time. The results indicated that total effect size for each variable could be affected 
by publication bias. However, analysis of funnel plots, which are relatively well-
balanced, indicated a lower probability of publication bias. When Orwin’s fail-safe 
N and funnel plot analysis are combined, the possibility of publication bias cannot 
be excluded.
3.3 Prevalence of NPA
Thirteen studies were included in the analysis of the prevalence of NPA in 
patients with PD. Data was classified into three distinct categories according to 
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reported NPA frequency: at least one lifetime NPA, one or more NPA in the past 
month, and two NPA per month or per 2 months with apprehensiveness about 
possible future NPA. For the latter criterion, the intensity of apprehensiveness 
about NPA had to be a minimum of four on a scale of 1–8. Finally, both NPA and 
Variable Effect 
size 
(Hedges’ g)
Confidence 
interval 
(95%)
Standard 
error
Variance Q I2 Number 
of 
studies
PD 
group 
sample 
size
Control 
group 
sample 
size
Sleep latency 0.81* [0.58, 1.04] 0.12 0.01 7.95 0.00 10 168 147
Sleep 
efficiency
−0.78* [−1.12, 
−0.43]
0.18 0.03 16.20** 50.62 9 186 118
Number of 
awakenings
0.07 [−0.25, 
0.40]
0.17 0.03 2.35 0.00 4 80 66
Total sleep 
time
−0.74* [−1.13, 
−0.35]
0.20 0.04 31.06** 67.80 11 209 164
Total wake 
time
0.58 [−0.20, 
1.36]
0.40 0.16 27.02** 81.49 6 88 68
REM sleep 
duration
−0.12 [−0.75, 
0.50]
0.32 0.10 4.15 51.76 4 65 51
REM sleep 
density
−0.04 [−0.41, 
0.32]
0.19 0.03 1.73 0.00 4 64 52
% REM sleep −0.01 [−0.22, 
0.20]
0.11 0.01 6.98 0.00 10 181 134
REM latency −0.25 [−0.73, 
0.24]
0.25 0.06 33.48** 76.10 9 187 140
Number of 
REM periods
0.04 [−0.60, 
0.67]
0.32 0.11 3.60 44.38 3 40 30
Slow-wave 
sleep 
duration
0.03 [−0.51, 
0.57]
0.28 0.08 — — 2 27 23
% slow-wave 
sleep
−0.07 [−0.42, 
0.28]
0.18 0.03 22.53** 60.05 10 174 132
Stage 1 
duration
0.25 [−0.36, 
0.87]
0.31 0.10 — — 2 19 19
Stage 2 
duration
−0.68* [−1.23, 
−0.12]
0.28 0.08 — — 2 27 23
% stage 1 
sleep
0.13 [−0.11, 
0.36]
0.12 0.01 3.71 0.00 9 164 137
% stage 2 
sleep
0.19 [−0.30, 
0.67]
0.25 0.06 39.89** 77.44 10 190 153
% stage 3 
sleep
0.31 [−0.38, 
1.00]
0.35 0.12 10.43** 71.24 4 97 54
% stage 4 
sleep
−0.31 [−1.10, 
0.47]
0.40 0.16 13.28** 77.41 4 97 54
Note: Q = weighted sum of squares, indicates total dispersion; I2 = proportion of variance due to real differences 
in effect size; PD = panic disorder; REM sleep = rapid eye movement sleep; slow-wave sleep = stages 3 and 4 sleep; 
— = insufficient number of studies to report heterogeneity; CI = confidence interval.
*= Significant differences between groups, p < 0.05.
**= Significant heterogeneity, p < 0.05.
Table 3. 
Meta-analysis results for polysomnographic and actigraphic data.
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apprehensiveness had to be present for at least the prior 6 months. A meta-analysis 
was performed for each of the three categories, with frequency of NPA in patients 
with PD and PD group sample size as input data. Results indicated that, among 
the pooled sample of patients with PD, an average of 52.1% (95% CI [46.4, 57.7]) 
reported at least one lifetime NPA (Table 4). The heterogeneity test revealed 
significant heterogeneity between studies and indicated that 73% of observed 
variance was attributed to true effects. The prevalence rate of one or more NPA 
in the past month was 27.0% (95% CI [17.9, 38.6]), and the heterogeneity test was 
significant. Sixty-five percent of observed variance was attributed to true effects. 
For recurrent NPA (2/month or/2 months with apprehensiveness about possible 
future NPA, intensity of apprehensiveness of minimally four on a scale of 1–8.), the 
mean prevalence rate was 40.9% (95% CI [18.1, 68.5]). As analyses included only 
two studies, heterogeneity was not calculated.
4. Discussion
This study was designed to use meta-analytic methodology to draw a detailed 
portrait of sleep disturbances in PD. More specifically, the primary objective was to 
compare sleep in this population to sleep in healthy controls. Results from subjective 
and objective data analysis confirmed the hypothesis that sleep quality in the former 
group is significantly poorer than in the latter group. Furthermore, in comparison 
to controls, patients with PD take longer to fall asleep and have more sleep distur-
bances and more difficulty with daytime functioning secondary to sleep problems. 
Analysis of objective sleep data revealed differences between patients with PD and 
healthy controls in sleep continuity parameters: patients with PD take longer to fall 
asleep, have a shorter sleep duration, and demonstrate poorer sleep efficiency. For 
the majority of sleep architecture parameters, no differences were noted between 
patients with PD and control participants, with the exception of stage 2 duration, 
which was shorter in patients with PD.
4.1 Self-report data
To date, some literature reviews have explored subjective sleep complaints in PD 
[3, 38–40]. They reported conclusions that are consistent with the data reported 
here, indicating that patients with PD report significant subjective sleep altera-
tions. However, most reviews did not detail the nature of these complaints. For 
example, Mellman [39] reported that there was subjective insomnia in patients with 
Frequency criteria Event rate 
(prevalence %)
Confidence 
interval (95%)
Q I2 Number 
of studies
Sample 
size
1 or more lifetime NPA 52.1 [46.4, 57.7] 36.51* 75.34 10 1647
1 NPA in the last month 27.0 [17.9, 38.6] 8.47* 64.59 4 224
2 NPA/month or /2 months 
with apprehensiveness 4/8, 
lasting at least 6 months
40.9 [18.1, 68.5] — — 2 221
Note: Q = weighted sum of squares, indicates total dispersion; I2 = proportion of variance due to real differences 
in effect size; PD = panic disorder; NPA = nocturnal panic attack; — = insufficient number of studies to report 
heterogeneity; CI = confidence interval.
*= Significant heterogeneity, p < 0.05.
Table 4. 
Meta-analysis results for NPA prevalence.
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PD, but without further specifying if there was a problem with sleep onset, sleep 
maintenance, or early awakenings. Only one recent systematic literature review has 
provided greater precision on subjective sleep complaints by reporting the results 
of nine previous studies in a structured manner [3]. This study reports a wide range 
of measures such as the sleep-wake experience list [45], the PSQI [18, 21, 46, 47], 
and the Goldberg depression and anxiety scales [48]. This unites useful and diverse 
information about the sleep of patients with PD. However, equivalence of measures 
and results synthesis remains difficult to judge. The statistical procedures of meta-
analysis that we used allowed us to carry out the said synthesis and provided easily 
understandable summary indicators (size effects) of the results.
The elevated level of heterogeneity in PSQI global scores constitutes one critical 
point for consideration in our analysis of subjective sleep data. Variation in effect 
sizes is significant, and the majority of variance (92.8%) is attributable to differ-
ences in true effects. The observed elevated level of heterogeneity may be attribut-
able to hidden covariates that moderate the differences between patients with PD 
and healthy controls. Previous research has identified subgroups of patients with 
PD in which insomnia might be more prevalent, including patients reporting NPA, 
depression [45], and greater anxiety sensitivity [18]. Effect sizes reported in each 
individual study may vary according to whether participants from these subgroups 
were included. Unfortunately, the number of studies reporting PSQI global scores 
was too low to permit the investigation of the impact of such variables via meta-
regression [32]. Further research addressing the impact of covariates such as NPA, 
depression, and anxiety sensitivity on sleep quality in PD patients is warranted.
4.2 Objective data
Among objective sleep variables, previous literature reviews reported impair-
ments in sleep continuity parameters. Reports of sleep onset latency, sleep effi-
ciency, and total sleep time alterations were the most cited and robust [3, 39, 40]. 
Some authors also mentioned that patients with PD have difficulty maintaining 
sleep [39], with higher percentage of wake time [40]. Combined effect sizes from 
our findings indeed confirm that patients with PD have shorter sleep, take longer to 
fall asleep, and have poorer sleep efficiency. However, they do not confirm previous 
findings regarding sleep maintenance, since total wake time and number of awak-
enings were similar in PD and control groups. Based on these results, the nature of 
sleep difficulties in PD seems to be restricted to sleep onset and early awakenings, 
rather than sleep maintenance.
Previous reviews highlighted the existing inconsistencies in sleep architecture 
data. Overall, they report that there is as much evidence showing that the sleep 
architecture of patients with PD and of healthy controls is different as there is 
evidence that they are not [3, 40]. The narrative nature of previous reviews limited 
the conclusions that could be drawn from such data. Given this limit, the present 
study used meta-analysis to synthesize conflicting data. Results showed no differ-
ence between the sleep of patients with PD and the sleep of healthy control par-
ticipants on the percentages of stage 1 and stage 2 sleep, of slow-wave sleep, and of 
REM sleep. Also, there were no differences between groups for the number of REM 
periods, REM sleep density and duration, stages 1 and 2 sleep duration, slow-wave 
sleep duration, and percentages of stage 3 and of stage 4 sleep. However, the latter 
results were less reliable due to the small number of studies that were included (two 
to four studies for each variable). Therefore, confirmation of the results is needed.
In sum, there is reliable evidence that, in comparison to healthy controls, patients 
with PD demonstrate alterations in objective sleep latency, sleep efficiency, and total 
sleep time. Also, it is plausible that percentages of REM sleep, of delta sleep, and of 
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stage 1 and stage 2 sleep do not differ between patients with PD and controls. For 
other variables, further research is required to confirm existing results.
4.3 Why is sleep altered in PD?
A recent literature review highlighted the need for studies to go beyond mere 
descriptions of sleep disturbances and to investigate the role of sleep disturbances 
in the development and maintenance of PD [3]. Research on the impact of cogni-
tive activity on sleep yielded important insights into the onset of insomnia in 
PD. Studies of the possible links between repetitive thought (e.g., worry or rumina-
tion) and various sleep characteristics in college students indicated that repetitive 
thoughts impact sleep [49]. Since patients with PD often worry about having 
panic attacks, it is possible that reported sleep alterations could be associated with 
repetitive worry about future panic. This hypothesis is consistent with Harvey’s [14] 
cognitive model of insomnia, which proposes that excess negative cognitive activity 
plays a central role in the maintenance of insomnia.
In patients with PD, the content of repetitive thinking often relates to possible 
panic attacks and their consequences. Patients develop a fear of anxiety itself, i.e., 
anxiety sensitivity [18, 50]. Researchers have found that, in patients with PD, anxi-
ety sensitivity is linked to insomnia and, in particular, to longer sleep latency [18]. 
Authors hypothesized that anxiety sensitivity makes patients monitor their anxiety 
signs and symptoms and could increase levels of cognitive, emotional, and physi-
ological activation [18]. This state of activation could disrupt the healthy course of 
sleep [18].
Sleep impairment caused by activation could be the beginning of a cycle where 
anxiety and insomnia mutually feed each other. Evidence suggests that sleep depri-
vation induces activation and anxiety in the general population [12] and increases 
the risk of panic in patients with PD [13]. Therefore, it is hypothesized that a sleep 
deficit could increase the risk of panic by inducing activation and anxiety. Indeed, 
since patients with PD fear signs of anxiety, the activation and anxiety caused by 
the sleep deficit trigger more anxiety that can culminate into panic attacks. These 
panic attacks could further disrupt sleep because of the activation state they caused 
and apprehensiveness. Future research should aim at verifying the hypothesis of the 
vicious cycle between panic and insomnia in order to better understand the cogni-
tive, behavioral, and emotional mechanisms behind the sleep disturbances identi-
fied in the present study.
The majority of the results issued from objective data were consistent with 
cognitive models of insomnia and PD. In contrast, the finding that patients with 
PD have shorter stage 2 sleep is not intuitive. One possible explanation for this 
result is the inclusion of patients with NPA. Since NPA usually occur between stage 
2 and stage 3 sleep, there may be a relationship between the presence of NPA and 
decreased stage 2 sleep. An alternative explanation is that shorter stage 2 sleep is 
an artifact of overall shorter sleep time. Since stage 2 sleep is the longest stage over 
the course of a night’s sleep (i.e., 45–55% of total sleep time; [51]), the changes in 
sleep continuity observed in our study (longer sleep latency, lower sleep efficiency, 
and shorter total sleep time) may be attributable to shorter sleep in all three stages. 
Since stage 2 occupies the majority of the night, it may be the only stage for which 
the change can be statistically detected. Indeed, the fact that the percentage of stage 
2 sleep observed in patients with PD does not differ significantly from that observed 
in control subjects supports this hypothesis.
Gathering detailed data on the nature of subjective and objective insomnia is 
a first step toward a greater understanding of the mechanisms (e.g., cognitions, 
anxiety sensitivity, repetitive thinking, etc.) through which insomnia could 
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maintain panic symptoms and vice versa. Nevertheless, the present review does not 
permit further inferences about interactions between sleep and PD. Considering 
that analyses of PSQI component scales, stages 1 and 2 sleep duration, slow-wave 
sleep (duration of slow-wave sleep, percentage of stages 3 and 4), and REM sleep 
(duration, density, number of REM periods) are based on a small number of studies 
(between two and four), further research is required to confirm the specific nature 
of sleep alterations, particularly regarding sleep architecture.
4.4 Nocturnal panic attacks
This study’s secondary aim was to estimate the prevalence rate of NPA. Results 
indicated that, among patients with PD, 52.1% (95% CI [46.4, 57.7]) experienced 
at least one lifetime NPA and 27.0% (95% CI [17.9, 38.6]) experienced at least 
one panic attack in the past month. Furthermore, 40.9% (95% CI [18.1, 68.5]) of 
patients with PD reported recurrent NPA (at least 1–2/month in the past 6 months) 
with apprehensiveness about possible future nocturnal attacks. Of the three 
estimates, the lifetime prevalence obtained here is the most precise and reliable, 
with a confidence interval ranging from 46.4 to 57.7%. This represents an improve-
ment compared to previously reported estimates: 44–71% in Lee and Douglass 
[38], 18–69% in Mellman [39], and 33–71% in Papadimitriou and Linkowski [40]. 
The two other NPA prevalence estimates calculated in our meta-analysis have 
wider confidence intervals, indicating poorer reliability. The poorer reliability may 
explain why the prevalence rate is higher using a more restrictive criterion (1/month 
or/2 months, with apprehensiveness, present since 6 months; 40.9%) than using a 
less restrictive criterion (one NPA in the past month; 27.0%). These results may be 
attributable to measurement error rather than to real differences in prevalence.
Some authors have proposed that NPA could be linked to abnormalities in 
breathing regulation and patterns [52]. Previous research has suggested that 
patients with PD have chronic hyperventilation [53], which would cause CO2 deple-
tion in the blood [54]. The metabolism would then adapt and become more sensi-
tive to small increases of CO2 in the blood [52]. Since non-REM sleep stages imply a 
reduced breathing rate and, therefore, a rise in CO2, authors propose that they could 
be sufficient to induce the physiological reactions and physical sensations that are 
feared by people with PD [54, 55]. Considering that there have been reports linking 
nocturnal panic to sleep apnea [56], we could hypothesize that sleep apnea could 
induce even stronger physiological sensations in people with CO2 hypersensitivity. 
Therefore, they would be more at risk of having NPA. However, the abnormalities 
in breathing regulation cannot totally explain the presence of NPA. Cognitive com-
ponents such as beliefs about physiological sensations and interoceptive condition-
ing still have to be present in order for NPA to occur.
4.5 Limitations
Interpretation of the present findings should take into account the following 
limitations. Some variables were reported by very few studies. For example, only 
two studies reported data on PSQI subscales, slow-wave sleep, and stage 1 and stage 
2 sleep duration. On the one hand, the limited data increases the risk of biased 
results, as there is no guarantee that the two included effect sizes are representative 
of the entire distribution of true effects [32]. On the other hand, a risk inherent to 
not running the analyses also exists, as it allows for the possibility of vote-counting, 
which is even more biased [32]. For example, Papadimitriou and Linkowski [40] 
discussed conflicting results about self-reported sleep efficiency. With only results 
of individual studies available, the authors could not draw concrete conclusions. 
Psychopathology - An International and Interdisciplinary Perspective
14
Our meta-analysis did not provide a clear conclusion either, but allowed us to 
contribute to the knowledge in this area by statistically synthesizing the data, taking 
into consideration the relative weight of each study, and providing a confidence 
interval for a true effect.
A significant number of studies with subjective sleep data could not be used 
because they used diverse self-report questionnaires. For example, a study by 
Batterham et al. in 2012 [48] was the only one to use the Goldberg depression and 
anxiety scale questions about sleep. While some of the data could have been merged 
into a single analysis designed to answer the question “Is there a significant differ-
ence in subjective sleep between patients with PD and healthy controls?”, such an 
analysis would not have provided information about specific sleep disturbances.
The majority of studies using PSQI did not report scores for the seven subscales. 
The inclusion of this data would have permitted a better comparison of subjective 
and objective sleep data. Previous research indicates that there is a misperception 
of sleep in some subjects with insomnia, who overestimate sleep onset latency and 
underestimate total sleep time [57, 58]. Conversely, other subjects tend to overes-
timate their total sleep time [58]. It would have been interesting to compare the 
results of the meta-analysis for subjective and objective sleep data. Future research 
should emphasize precision in reports of subjective sleep complaints.
The absence of standards in NPA reporting complicated study comparison, 
with the result that many studies were excluded from our estimates. Moreover, few 
authors specified whether or not apprehensiveness about possible future NPA was 
present. As discussed previously, the presence of apprehensiveness is important 
because it is hypothesized to increase arousal and maintain insomnia. In the absence 
of apprehensiveness, interactions between NPA, insomnia, and PD are less clear. 
We therefore suggest the use of standardized frequency criteria for NPA prevalence 
that include apprehensiveness about future NPA. The criterion used by Craske et al. 
[59] and Albert et al. [60] constitutes a good example. The use of a standardized 
measure of NPA (e.g., the appendix to ADIS-IV for NPA) would contribute to the 
generation of standardized data. This section of the ADIS-IV is clinician-admin-
istered; developing a self-report version could also make standardized evaluation 
of NPA more accessible. However, since ADIS-IV has been updated to ADIS-5, an 
update of the appendix to DSM-5 criteria is needed before any other developments 
take place.
5. Conclusion
In conclusion, this systematic literature review confirms the presence of both 
subjective and objective insomnia in patients with PD. The results indicate that 
sporadic NPA are common in this population, i.e., more than one in every two 
patients with PD (52.1%) report at least one lifetime NPA. Recurrent NPA with 
apprehensiveness about future episodes seems to be slightly less common (40.9%) 
and is hypothesized to trigger and maintain insomnia. However the reliability of 
this last prevalence is low and needs confirming in future research.
We would like to emphasize the importance of using standardized psychomet-
ric tools such as the PSQI when reporting research data about sleep in patients 
with PD. Moreover, reporting results for subscales could give a better and more 
complete idea of the type of sleep alterations patients are experiencing. Also, 
research in this area would benefit from greater standardization in reports of 
subjective sleep and NP, and from particular attention in detailing subscales and 
information about diverse sleep variables (e.g., sleep latency, sleep efficiency, 
awakenings, etc.).
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Finally, we would like to highlight the need for new research reporting poly-
somnographic data from patients with PD. Indeed, many of the studies included in 
our review were completed over 20 years ago. With the publication of DSM-5, the 
need for current data is even greater. Such studies could also be designed to help 
understand the cognitive processes by which insomnia is generated and maintained. 
Polysomnographic studies could also help understand the role of sleep-disordered 
breathing in NPA. Further study of sleep in patients with PD is particularly impor-
tant because sleep problems are associated with poorer outcomes in individuals 
presenting psychopathology [61, 62]. Given the link between PD and sleep distur-
bances, such research could yield significant benefits for clinical evaluation and 
treatment of patients with PD.
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